Genmab

From early discovery through development and delivery, we are working to ensure our medicines reach patients. Watch how we’re taking ownership of the full antibody journey with the ambition to drive greater progress for patients and the future of medicine. #AntibodyScience #Innovation #PatientFirst 

By 2050, the number of women diagnosed with ovarian cancer is projected to rise by more than 55%, impacting more than half a million globally (1).    On World Ovarian Cancer Day, we stand with women everywhere along with the global community working to drive greater awareness, earlier diagnosis, and improved care.    #WorldOvarianCancerDay #OvarianCancer    1 Global Cancer Observatory (GCO). International Agency for Research on Cancer, World Health Organization. Estimated numbers from 2022 to 2050, females aged 0–85+. 

#InvestorUpdate: Genmab has published its first-quarter interim report highlighting the strength of our pipeline, including our portfolio of wholly owned programs.  Hear from our executive leaders as they share how we are advancing our late-stage pipeline of innovative antibody products with the ambition to transform the treatment of cancer and other serious diseases.  Learn more: https://lnkd.in/e-wjdjCm. #Innovation #Biotech  

From a silent scream to a powerful voice. When Portia first heard the words, “You have cancer,” her reaction was internal, something many patients understand all too well. But her journey didn’t stop there. During this edition of #AntibodyHour 🕙 hear from Portia Badham, Patient Advisor, who is helping shape the future of cancer treatment by ensuring patient voices are heard where it matters most. Her story is a powerful reminder that innovation in cancer care isn’t just about science; it’s about partnership. When patients and researchers work together, better support for patients becomes possible. Watch and hear how lived experience is driving meaningful change in oncology. Read more: https://lnkd.in/gZrxrdci. #PatientFirst 

Welcome to Genmab’s May Edition of Knock-Your-Socks-Off-News, a monthly newsletter covering our current happenings across the globe. Follow along with us on our journey for more updates as we advance innovation and continue to work towards our goal of transforming the lives of patients through antibody medicines.     #culture  #news  #healthcare 

"I believe breakthrough science can be a miracle for a patient and her family.” - Robin Cohen     #ICMYI: In a recent edition of #AntibodyHour 🕙, we spotlighted the voices that inspire our work. In this episode, Robin Cohen, BSN, CEO of Sandy Rollman Ovarian Cancer Foundation, reflects on her time as an oncology nurse and the moments that changed her life.     She shares the powerful message from one of her patients that has become her compass: “You go out and you fight for us."    Robin reminds us that “a win” looks different for every patient. Some ask, “How long will I live?” Others ask, “How will I live?” Those questions challenge all of us as scientists, clinicians, and colleagues to focus on what truly matters to each individual patient and their family. At Genmab, stories like these are more than inspiring, they are grounding. They remind us why breakthrough science matters, why urgency matters, and why every antibody we work on carries our aspiration to transform the lives of patients.     #PatientFirst

We’re proud to share that our colleagues Amy Yancy Whited, MBA, Regional Director, State Government Affairs and Mandy Y., Vice President, Head of Development Program Management were honored as a Luminaries along with and Laura Højland Larsen, Associate Director, Global Drug Safety & Pharmacovigilance Scientist who was recognized as a Rising Star at the Healthcare Businesswomen's Association - Entrepreneurship (HBA)’s Woman of the Year event!      These awards recognize exceptional leadership, impact, and contributions across the healthcare and pharmaceutical industry. We celebrate their accomplishments and are grateful for their leadership and dedication to driving positive change for patients.      #HBAWOTY2025 

We are proud to share that Genmab’s CEO, Jan van de Winkel, Ph.D., has been named CEO of the Year by DANISH BIO - DANSK BIOTEK at this year’s Spring Gala. The award recognizes Jan’s strong leadership and his continued dedication to patients, and to advancing innovative antibody research and contributing to the life-science ecosystem globally.     Under his leadership, Genmab continues to evolve into an integrated biotech, with Jan playing a central role in shaping that journey. His leadership continues to guide the company’s core purpose of making an impact on patients’ lives.     With our strong Danish roots, receiving this recognition from Danish Bio makes it particularly meaningful and reflects Genmab’s continued contribution to the Danish life science ecosystem.    #Leadership #Biotech #Innovation #Genmab 

In honor of Earth Day, our teams in China, Denmark, the Netherlands, and the U.S. came together to give back through hands-on volunteer efforts. Activities ranged from planting cherry blossom trees to building beehives and birdhouses, as well as organizing beach, river, and community cleanups.      We also supported global reforestation efforts through a donation to One Tree Planted, helping restore forests and strengthen communities impacted by wildfires.      Through these collective actions, we aim to contribute to a healthier, more sustainable future.     #CommunityAtGenmab #EarthDay 

Head and neck squamous cell carcinoma (HNSCC) can be difficult to treat, especially in advanced disease, and it can profoundly affect everyday activities, including speaking, swallowing, and interacting with others (1). These realities highlight the importance of awareness, education, and collaboration to help advance research and care for people living with HNSCC. Genmab stands with the HNSCC community and supports partners working every day to close gaps in awareness and care. Meaningful progress can happen when patients, advocates, researchers, clinicians, and industry work together. #HeadandNeckCancerAwareness #HNSCC 1 McCartney J. Rising incidence of head and neck cancer drives treatment advances. Bull Am Coll Surg. October 2025;110(9). https://lnkd.in/e62teXmj